Title:
シクロホスファミド療法に対する応答者の予測
Document Type and Number:
Japanese Patent JP7255896
Kind Code:
B2
Abstract:
The present disclosure is based on detecting CC chemokine receptor 4 (CCR4) expression on T effector cells to diagnostically or prophylactically predict subjects, in particular those with a gynaecological cancer who will respond to treatment with low dose cyclophosphamide.
Inventors:
Plevansky, Magdalena
Madondo, Mutosa Tatenda
Madondo, Mutosa Tatenda
Application Number:
JP2020514307A
Publication Date:
April 11, 2023
Filing Date:
May 18, 2018
Export Citation:
Assignee:
ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY
International Classes:
G01N33/574; A61K31/675; A61K35/768; A61K38/19; A61K39/00; A61K39/395; A61K45/00; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| JP2015526709A | ||||
| JP2015512616A |
Foreign References:
| WO2013114367A2 |
Other References:
FOUCHER, E. D. et al.,IL-34- and M-CSF-induced macrophages switch memory T cells into TH17 cells via membrane IL-1α,European Journal of Immunology,2015年,Vol.45,p.1092-1102
MADONDO, M. T. et al.,Low dose cyclophosphamide: Mechanisms of T cell modulation,Cancer Treatment Reviews,2016年,Vol.42,p.3-9
MADONDO, M. T. et al.,Low dose cyclophosphamide: Mechanisms of T cell modulation,Cancer Treatment Reviews,2016年,Vol.42,p.3-9
Attorney, Agent or Firm:
Patent Attorney Corporation Hiraki International Patent Office